Breast cancer affects approximately one in ten women and is therefore a major health problem. In order to improve the diagnosis, treatment and prognosis of this disease, it is critical to understand the molecular defects which contribute to disease initiation and progression. Over the last twenty years significant progress has been made in this regard, however there still remain a considerable number of unanswered questions. For example, it is not yet clear which are the most critical molecules ....Breast cancer affects approximately one in ten women and is therefore a major health problem. In order to improve the diagnosis, treatment and prognosis of this disease, it is critical to understand the molecular defects which contribute to disease initiation and progression. Over the last twenty years significant progress has been made in this regard, however there still remain a considerable number of unanswered questions. For example, it is not yet clear which are the most critical molecules contributing to this disease and thus which are the best targets for therapeutic intervention. In this proposal, we aim to study two molecules. The first is called BRCA1 and is particularly important in inherited susceptibility to breast cancer. The second is called PML and, although originally described as a leukaemia-associated gene, it has since been implicated in a number of cancers. Specifically, we aim to investigate the possibility that PML and BRCA1 work together to protect against cancer and that they do this by regulating the ends of chromosomes, that is, the telomeres.Read moreRead less
Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
Exploring Roles For MicroRNAs In Cancer Using Bioinformatics And Gene Expression Tools.
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
microRNAs are newly discovered chemicals that were the subject of the 2006 Nobel Prize in Medicine. These chemicals decrease the amount of specific molecular ‘targets’ in cells, and play an important role in cancer. Currently we do not understand how these chemicals choose their targets, and we propose to use a computer-based approach to discover how they affect genes in cancer. This will improve our understanding of cancer and thereby lead to the discovery of novel anti-cancer therapies.
Studies in humans and model organisms have shown that defects in centromere function result in chromosome abnormalities and copy-number changes that constitute a major cause of aneuploid-related syndromic disorders, intellectual disability, infertility, pregnancy loss, and cancer. Understanding the biological properties and functions of the centromere is therefore a high priority for health research.